DHEA and Men's TRT: Everything You Need to Know About Testosterone Formulations

What Is DHEA and Why Does It Matter in Men's Hormone Health?

DHEA is the most abundant circulating steroid in the human body, and its serum concentration falls sharply with age. Produced mainly in the zona reticularis of the adrenal cortex, DHEA and its sulfate form DHEA-S act as precursor molecules that peripheral tissues convert into testosterone and estradiol [1]. By age 70, 80, most men have DHEA-S levels that are 10 to 20% of their peak young-adult values [2].

That decline matters clinically. Low DHEA-S has been associated with increased all-cause mortality in older men in the Massachusetts Male Aging Study [3], reduced lean mass, and worse insulin sensitivity. A 2020 meta-analysis published in The Journal of Clinical Endocrinology and Metabolism (N=1,243 across 25 RCTs) found that DHEA supplementation produced statistically significant improvements in body composition and sexual function scores compared with placebo, though effect sizes were modest [4].

DHEA supplements are sold over the counter in the United States in doses from 10 mg to 100 mg. However, OTC formulations bypass the prescribing and monitoring that prescription TRT carries, which means serum conversion to estradiol can go untracked. Clinicians at HealthRX typically check a baseline DHEA-S, total testosterone, free testosterone, and estradiol before adding DHEA to any TRT protocol.

The Endocrine Society's 2010 Clinical Practice Guideline states: "We recommend against the routine prescription of DHEA to all older men, but acknowledge its use in men with documented adrenal insufficiency after weighing risks and benefits" [5]. That guidance has shaped prescribing conservatism, but individual cases, particularly men with low-normal DHEA-S alongside symptomatic hypogonadism, may still benefit from targeted supplementation alongside prescription testosterone.

How DHEA Converts to Testosterone in Men

DHEA does not act like testosterone directly. Peripheral tissues, including skeletal muscle, liver, and skin, contain the steroidogenic enzymes 3-beta-hydroxysteroid dehydrogenase and 17-beta-hydroxysteroid dehydrogenase that convert DHEA into androstenedione and then into testosterone [6]. A parallel aromatase pathway converts androstenedione into estrone and then estradiol.

This dual-conversion pathway is why DHEA supplementation raises both testosterone and estrogen in men. A randomized crossover trial published in JAMA (N=280) found that oral DHEA 50 mg daily for 12 months raised serum testosterone by roughly 18% in men over age 65 but also raised estradiol by approximately 14% [7]. Neither change was large enough to replicate the hormonal profile achieved by prescription testosterone injections, which is why DHEA functions as a complement rather than a replacement in most TRT protocols.

Sublingual and transdermal DHEA preparations bypass first-pass hepatic metabolism and may produce higher serum DHEA-S concentrations per milligram than oral capsules [8]. Regardless of delivery route, any man taking DHEA alongside injectable testosterone should have serum estradiol (sensitive assay), hematocrit, and DHEA-S monitored every 3 months during dose titration.

Testosterone Cypionate: The Most Commonly Prescribed Injectable in the United States

Testosterone cypionate is an esterified testosterone dissolved in cottonseed oil, FDA-approved under the brand name Depo-Testosterone and widely available as a generic [9]. Its half-life is approximately 8 days, making weekly or biweekly dosing practical for most men.

The standard TRT starting dose is 100 to 200 mg injected intramuscularly or subcutaneously every 7 to 14 days, with titration guided by trough serum testosterone drawn just before the next injection. The AUA's 2018 guidelines on evaluation and management of testosterone deficiency recommend a target trough of 400 to 700 ng/dL for most symptomatic men [10].

A 2017 study in The Journal of Urology (N=152) found that men on testosterone cypionate 200 mg every 2 weeks experienced significant trough-to-peak hormone swings, with trough testosterone dropping below 300 ng/dL in 41% of subjects by day 14 [11]. Switching to 100 mg weekly reduced that variability substantially and correlated with fewer mood fluctuations and improved sexual function scores. Weekly injections are now the dominant prescribing pattern in U.S. TRT clinics.

Subcutaneous administration of testosterone cypionate has gained acceptance as an alternative to intramuscular injection. A pharmacokinetic study in Postgraduate Medicine (N=37) demonstrated that subcutaneous injection produced equivalent steady-state testosterone levels with less injection-site pain [12]. HealthRX providers often start patients on subcutaneous protocols for home self-administration.

Hematocrit elevation is the most clinically significant adverse effect. The FDA prescribing information for testosterone cypionate notes polycythemia as a known risk requiring monitoring [9]. Men should have a complete blood count at baseline, at 3 months, and annually thereafter.

Testosterone Enanthate: The Global Standard

Testosterone enanthate is the most widely used injectable testosterone outside the United States. It shares an identical active hormone with cypionate but carries a slightly shorter ester chain, giving it a half-life of approximately 4.5 days compared with cypionate's 8 days [13].

Branded as Delatestryl in the United States and available in generic form, enanthate is dissolved in sesame oil rather than cottonseed oil. Men with cottonseed-oil sensitivity, though uncommon, may tolerate enanthate better. Dosing follows similar principles: 100 to 200 mg every 7 to 10 days for TRT, with more frequent administration (every 5 days) preferred when minimizing peak-to-trough fluctuation is a priority.

A pharmacokinetic head-to-head comparison published in the Journal of Clinical Pharmacology found no statistically significant difference in testosterone AUC between 200 mg enanthate and 200 mg cypionate given intramuscularly, with both achieving peak serum concentrations at approximately 24 to 72 hours post-injection [14]. In practical prescribing, provider familiarity and pharmacy availability are the main differentiators.

The Testosterone Trials (TTrials), a coordinated set of seven double-blind placebo-controlled trials published in the New England Journal of Medicine (N=790 men, aged 65 and older), used testosterone gel rather than injections, but established the foundational benefit data for testosterone therapy in older men: significant improvements in sexual function, physical function, and bone mineral density at 1 year [15]. These findings apply directionally to injectable formulations as well.

Testosterone Propionate: The Short-Ester Option

Testosterone propionate has the shortest ester among the three injectable options discussed here, with a half-life of approximately 2 days [16]. It requires injections every 2 to 3 days to maintain stable serum levels, which reduces its appeal as a primary TRT agent for most men.

Its faster clearance does offer one practical advantage: men who experience adverse effects (excess estradiol conversion, acne, mood disturbance) can clear the hormone within days of stopping, rather than waiting the 2 to 3 weeks it takes for cypionate to wash out. Some TRT protocols use propionate during the initial titration phase for that reason.

Propionate is dissolved in various oils and is available through compounding pharmacies in the United States, since the main branded products were discontinued. A 1998 pharmacokinetic study in Clinical Endocrinology (N=12) confirmed that intramuscular testosterone propionate 50 mg produced peak serum testosterone of approximately 1 to 000 ng/dL at 24 hours, falling to 400 ng/dL by 72 hours, which illustrates the dosing demand [17]. Without every-other-day injections, troughs fall below the therapeutic range.

Men with needle aversion are rarely good candidates for propionate-based protocols. The burden of frequent injections outweighs the washout advantage for the majority of TRT patients.

Testosterone Pellets: Long-Acting Subdermal Delivery

Testosterone pellets (brand name Testopel, and several compounded alternatives) are inserted subcutaneously, typically in the upper buttock or flank, through a minor in-office procedure performed under local anesthesia [18]. Each pellet contains crystalline testosterone without an ester. Pellets dissolve via hydrolysis over 3 to 6 months, producing a relatively flat serum testosterone curve with fewer peak-to-trough swings than weekly injections.

Standard dosing is 6, 12 pellets (75 mg each) per insertion, with the number determined by body weight, baseline testosterone, and symptom severity. A prospective study in Menopause that included male data (N=163 men) found mean serum testosterone of 612 ng/dL at 6 weeks post-insertion, declining to 496 ng/dL at 24 weeks [19]. Reinsertion is scheduled when symptoms recur or trough testosterone falls below 400 ng/dL.

The primary complications of pellet insertion are extrusion (pellets being expelled through the insertion site, reported in approximately 2 to 10% of insertions in published case series) and local infection (under 1%) [20]. Hematocrit and PSA monitoring requirements are identical to injectable testosterone because total androgen exposure is comparable.

One clinical advantage pellets carry over injectables: no home self-injection is required. For men who travel frequently, find injections inconvenient, or have needle phobia, pellets can dramatically improve adherence over a 12-month period.

How DHEA Fits Into an Injectable or Pellet TRT Protocol

Adding DHEA to a prescription testosterone protocol is not standard practice for all men, but specific clinical scenarios make it rational. Men who have documented adrenal insufficiency, suppressed DHEA-S despite normal testosterone replacement, or who report persistent fatigue and low libido that does not fully resolve with testosterone alone are candidates for evaluation [5].

Serum DHEA-S below 100 mcg/dL in a symptomatic man under age 60 warrants clinical attention. A 12-week RCT in the European Journal of Endocrinology (N=67 men with adrenal insufficiency) found that adding DHEA 50 mg daily to stable glucocorticoid replacement improved subjective well-being scores by 30% compared with placebo (P<0.001) [21]. That population has documented adrenal DHEA deficiency, making replacement directly analogous to testosterone replacement in hypogonadism.

For men on TRT who have normal adrenal function, the evidence is more conditional. A trial in JAMA Internal Medicine (N=206 men, aged 60, 79) found that DHEA 75 mg daily for 2 years did not significantly improve lean mass or muscle strength beyond the effects of resistance training alone [22]. Prescribing DHEA in this context requires a clear clinical rationale and informed-consent discussion about the modest evidence base.

When DHEA is added to a testosterone cypionate or enanthate protocol, the practical starting dose is 25 to 50 mg orally each morning (mimicking the natural diurnal peak of adrenal androgen secretion). Estradiol should be rechecked 6 weeks after initiation because DHEA can increase aromatization and may require an aromatase inhibitor adjustment.

Choosing Between Formulations: A Clinical Decision Framework

No single testosterone formulation is right for every man. The decision involves pharmacokinetics, lifestyle, administration tolerance, and cost. The following considerations guide HealthRX clinicians in that conversation.

Injection frequency tolerance is often the deciding factor. Men comfortable with weekly self-injection gravitate toward cypionate or enanthate. Men unwilling to self-inject favor pellets, which require only 2, 4 clinic visits per year.

Ester-related oil sensitivity is rare but real. Cottonseed oil (cypionate) and sesame oil (enanthate) allergies have been reported; switching esters resolves the reaction in most cases [23].

Hormone stability goals differ by individual. Athletes or men sensitive to mood changes tend to prefer shorter dosing intervals (100 mg cypionate weekly or enanthate every 5 days) over longer ones, because peak-to-trough swings are smaller [11]. Pellets produce the flattest serum curve of all options.

Estradiol management is more straightforward with injectables because dose adjustments take effect within days. With pellets, a dose correction requires waiting for the current pellet batch to dissolve, which can take months. Men with a history of high aromatization may be better served by injectables initially.

Cost and access vary by region and insurance coverage. Generic testosterone cypionate is among the least expensive prescription medications in the United States, often under 30 dollars per month at standard TRT doses [9]. Pellet insertion carries a procedure fee (typically 300, 600 dollars per insertion) that insurance may not reimburse.

Monitoring Testosterone Therapy: What Labs Are Required and When

All testosterone formulations, whether supplemented with DHEA or not, require structured laboratory monitoring. The American Urological Association and the Endocrine Society both specify a minimum monitoring schedule [5][10].

At baseline, men should have: total testosterone (morning draw), free testosterone, LH, FSH, PSA, complete blood count (hematocrit), comprehensive metabolic panel, and estradiol (sensitive assay). DHEA-S should be added if adrenal deficiency is suspected or if the man is over 50.

At 3 months after initiating therapy: repeat total testosterone (trough for injectables), hematocrit, estradiol, and PSA. Dose adjustments are made at this point.

At 12 months and annually thereafter: full panel including bone mineral density (DEXA) after 2 years if baseline was low.

Hematocrit above 54% requires dose reduction or therapeutic phlebotomy [10]. PSA increase of more than 1.4 ng/mL above baseline in the first year, or absolute PSA above 4.0 ng/mL, requires urology referral before continuing therapy. These thresholds come directly from the 2018 AUA testosterone deficiency guidelines.

A 2019 retrospective cohort study in JAMA Internal Medicine (N=5,450 men on TRT over 36 months) found that men who adhered to recommended monitoring schedules had a 23% lower rate of adverse cardiovascular events compared with those who were monitored less frequently, though the study design cannot establish causation [24].

Safety Considerations: Cardiovascular Risk, Fertility, and Prostate

The cardiovascular safety of TRT has been debated for over a decade. The TRAVERSE trial (N=5,204 men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk), published in the New England Journal of Medicine in 2023, found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months [25]. Atrial fibrillation and acute kidney injury were more common in the testosterone group, both statistically significant findings requiring consideration in men with pre-existing cardiac conditions.

Fertility suppression is an expected consequence of exogenous testosterone administration. Exogenous testosterone suppresses LH and FSH through hypothalamic-pituitary feedback, reducing intratesticular testosterone and spermatogenesis [26]. Men who want to preserve fertility should avoid exogenous testosterone and consider clomiphene citrate or hCG-based protocols instead.

Prostate safety data from the TTrials showed no significant increase in prostate cancer incidence over 1 year of treatment in men with baseline PSA below 3.0 ng/mL [15]. The Endocrine Society guideline does not list a history of treated, low-risk prostate cancer as an absolute contraindication, but recommends shared decision-making and close urologic follow-up [5].

DHEA-specific safety concerns center on androgenic side effects (acne, hair thinning) and estrogen-dependent conditions. Men with a personal history of hormone-sensitive tumors should avoid DHEA supplementation without specialist input.